Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 8Completed 4Unknown 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 67Stomach Neoplasms 4Ovarian Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Inflammatory Breast Neoplasms 3Breast Neoplasms, Male 3Solid Tumor 2Rectal Neoplasms 2Prostatic Neoplasms 2HER2-positive Breast Cancer 2Colonic Neoplasms 2Carcinoma, Ductal, Breast 2Urinary Bladder Neoplasms 1Solid Cancers 1Patient Preference 1Neoplasms, Unknown Primary 1Metastatic HER2-Positive Breast Cancer 1Lung Neoplasms 1Her2-Positive Breast Cancer 1HER2-positive Early Breast Cancer 1HER2-Positive Early Breast Cancer 1HER2 Positive Breast Cancer 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Elderly Metastatic Breast Cancer Population 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Neoplasms × pertuzumab × Clear all
NCT07416409 2026-02-18

Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer

Deraya University

Completed
80 enrolled
Breast

Breast Neoplasms, Neoplasms

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

Phase 2 Completed
673 enrolled 22 charts
GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT00027027 2015-07-27

Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors

Genentech, Inc.

Phase 1 Completed
21 enrolled 17 charts
Tumor-Agnostic

Neoplasms

NCT00096993 2015-06-10

A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Genentech, Inc.

Phase 2 Completed
131 enrolled 11 charts
Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡